Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Director Joseph L. Goldstein sold 2,125 shares of the firm’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $450.00, for a total transaction of $956,250.00. Following the sale, the director now owns 15,125 shares in the company, valued at approximately $6,806,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) opened at 429.63 on Wednesday. The company has a 50-day moving average of $382.11 and a 200 day moving average of $387.86. The stock has a market cap of $45.04 billion, a P/E ratio of 62.68 and a beta of 1.79. Regeneron Pharmaceuticals Inc. has a 52-week low of $325.35 and a 52-week high of $592.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.73 by $0.40. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The company earned $1.22 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter last year, the company earned $3.47 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 7.3% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals Inc. will post $11.73 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Hedge funds have recently modified their holdings of the stock. Fisher Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 1.1% in the third quarter. Fisher Asset Management LLC now owns 620 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 7 shares during the last quarter. Wetherby Asset Management Inc. increased its stake in Regeneron Pharmaceuticals by 2.3% in the second quarter. Wetherby Asset Management Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 18 shares during the last quarter. Waldron LP increased its stake in Regeneron Pharmaceuticals by 2.1% in the third quarter. Waldron LP now owns 856 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 18 shares during the last quarter. Fagan Associates Inc. increased its stake in Regeneron Pharmaceuticals by 2.5% in the second quarter. Fagan Associates Inc. now owns 820 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 20 shares during the last quarter. Finally, American Money Management LLC increased its stake in Regeneron Pharmaceuticals by 3.3% in the second quarter. American Money Management LLC now owns 785 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 25 shares during the last quarter. 68.58% of the stock is owned by institutional investors.

Several analysts have recently issued reports on REGN shares. JPMorgan Chase & Co. set a $477.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, October 30th. Piper Jaffray Cos. set a $447.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, October 30th. Cowen and Company set a $430.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, October 30th. Canaccord Genuity set a $450.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, November 6th. Finally, Leerink Swann set a $511.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, August 6th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $471.05.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.